Atara Biotherapeutics to present clinical results of Car T platform
Category: #health  By Pankaj Singh  Date: 2019-03-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Atara Biotherapeutics to present clinical results of Car T platform
  • The firm is looking forward to its MSK collaborators’ clinical outcomes of a mesothelin-targeted autologous CAR T for patients suffering from advanced malignant pleural ailment
     
  • The event is slated to be held from March 29 to April 3 at Atlanta, Georgia

Atara Biotherapeutics, Inc. has reportedly declared that it would present the clinical safety and efficacy results of mesothelin-targeted CAR T and next-generation CAR T platform at the annual meeting of the American Association of Cancer Research (AACR). As per trusted sources, the clinical results are from Memorial Sloan Kettering Cancer Center.

According to a press release from Atara Biotherapeutics, the event is slated to be held from March 29 to April 3 at Atlanta, Georgia. For the record, Mesothelin is a solid tumor-related antigen which is expressed at higher levels on the surface of cells in hostile solid tumors including non-small cell lung cancer, pancreatic cancer, ovarian cancer, triple-negative breast cancer, and mesothelioma.

Global Head of Research and Development at Atara Biotherapeutics, Dietmar Berger, M.D., Ph.D. was reportedly quoted saying that the company has established one of the foremost CAR T portfolios. The pre-clinical results presented at the AACR show are encouraging and show the potential of the firm’s EBV-specific T cell platform to develop allogeneic, off-the-shelf CAT T immunotherapies, Berger further added.

Reportedly, Atara Biotherapeutics is looking forward to its MSK collaborators’ clinical outcomes of a mesothelin-targeted autologous CAR T to treat patients suffering from advanced malignant pleural ailment.

Preliminary outcomes from the MSK sponsored Stage 1 study (currently in progress) of a mesothelin-targeted CAR T immunotherapy for patients with malignant plural cancers were exhibited at the 2018 annual meeting of American Society of Gene and Cell Therapy.

Atara had signed an exclusive collaboration and license deal with MSK in Jan this year to create a mesothelin-targeted CAR T by utilizing PD-1 dominant negative receptor (DNR) and 1XX CAR signaling domain checkpoint inhibition technologies.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

vTv Therapeutics unveils additional positive data from diabetic study
vTv Therapeutics unveils additional positive data from diabetic study
By Pankaj Singh

TTP399 increased Time in Range, reduced hyperglycemia time, a bolus insulin dose that was lower and fewer hypoglycemic events.   TTP399 could be placed for Phase 3 development to address Type 1 Diabetes. vTv Therapeutics Inc., a biopharmac...

Westlake to advise Frontier Energy on its takeover of Energy Insight
Westlake to advise Frontier Energy on its takeover of Energy Insight
By Pankaj Singh

Energy efficiency is becoming a point of focus for several companies operating across the world. Various firms worldwide are turning towards energy efficiency consulting companies to efficiently manage the energy they use. This not only saves energy ...

Rocket Pharma unveils Phase 1/2 trial data for its Fanconi Anemia drug
Rocket Pharma unveils Phase 1/2 trial data for its Fanconi Anemia drug
By Pankaj Singh

The manuscript includes data of the first four trial participants that were treated with RP-L102 under the Phase 1/2 FANCOLEN-I study.   First RP-L102 trail data demonstrates increase in bone marrow engraftment levels, which further leads to...